- Home
- IKT vs CRBU Comparison
IKT vs CRBU Comparison
Compare IKT & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- CRBU
- Stock Information
- Founded
- IKT 2008
- CRBU 2011
- Country
- IKT United States
- CRBU United States
- Employees
- IKT N/A
- CRBU N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- IKT Health Care
- CRBU Health Care
- Exchange
- IKT Nasdaq
- CRBU Nasdaq
- Market Cap
- IKT 159.2M
- CRBU 151.2M
- IPO Year
- IKT 2020
- CRBU 2021
- Fundamental
- Price
- IKT $2.27
- CRBU $1.47
- Analyst Decision
- IKT Strong Buy
- CRBU Strong Buy
- Analyst Count
- IKT 2
- CRBU 5
- Target Price
- IKT $6.50
- CRBU $11.80
- AVG Volume (30 Days)
- IKT 194.9K
- CRBU 1.6M
- Earning Date
- IKT 03-26-2025
- CRBU 03-10-2025
- Dividend Yield
- IKT N/A
- CRBU N/A
- EPS Growth
- IKT N/A
- CRBU N/A
- EPS
- IKT N/A
- CRBU N/A
- Revenue
- IKT $1.00
- CRBU $11,475,000.00
- Revenue This Year
- IKT N/A
- CRBU N/A
- Revenue Next Year
- IKT N/A
- CRBU N/A
- P/E Ratio
- IKT N/A
- CRBU N/A
- Revenue Growth
- IKT N/A
- CRBU N/A
- 52 Week Low
- IKT $1.12
- CRBU $1.30
- 52 Week High
- IKT $4.20
- CRBU $8.33
- Technical
- Relative Strength Index (RSI)
- IKT 38.70
- CRBU 39.57
- Support Level
- IKT $1.90
- CRBU $1.30
- Resistance Level
- IKT $2.37
- CRBU $1.57
- Average True Range (ATR)
- IKT 0.25
- CRBU 0.08
- MACD
- IKT -0.07
- CRBU 0.01
- Stochastic Oscillator
- IKT 34.91
- CRBU 44.46
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.